Near the end of the year, many enterprises in China's pharmaceutical industry get subsidies!

[China Pharmaceutical network industry news] near the end of this year, a number of listed companies announced that they had received government subsidies or subsidies According to industry statistics, as of December 26, 65 companies announced that they had received subsidies and subsidies, ranging from hundreds of thousands of yuan to hundreds of millions of yuan And from the current announcement, machinery manufacturing industry, emerging industry and pharmaceutical industry get more subsidies Among them, in the machinery manufacturing industry, three enterprises, namely new Hualian, Sany Heavy Industry and BAIC bluevale, received subsidies of more than 100 million yuan In the emerging industries, semiconductor, artificial intelligence and other industries have become the key industries of subsidies The industry said that, especially the artificial intelligence industry, will become a highly valued field in China, and relevant policies will continue In the pharmaceutical industry, Huabei pharmaceutical, Huahai pharmaceutical, and Tailong pharmaceutical received subsidies of more than 50 million yuan And North China Pharmaceutical received more subsidies The author combs the pharmaceutical companies that have been subsidized in the past two months The specific situation is as follows Huabei Pharmaceutical Co., Ltd announced on the evening of December 24th that the company received 72 million 959 thousand and 500 yuan of subsidy from Shijiazhuang employment service center on 24 days, and the company and its subsidiaries have received 73 million 730 thousand and 700 yuan of government subsidy since October 19th, all of which are related to income According to the public data, the operating revenue of North China Pharmaceutical in the first three quarters was 7.08 billion yuan, an increase of 24.25% year-on-year; the net profit was 76.93 million yuan, an increase of 254.32% year-on-year Huahai pharmaceutical announced on December 25 that recently, the company received a government subsidy of 18 million yuan issued by Linhai Finance Bureau The subsidy is expected to affect the company's current profit and loss by 18 million yuan According to public information, due to the Valsartan incident, the first three quarters of this year's performance of Huahai pharmaceutical "report card" is not ideal According to the data, the company's operating revenue in the first three quarters was about 3.843 billion yuan, up 9.48% year on year, while its net profit was about 255 million yuan, down 47.38% year on year The company received a total subsidy of about 1.07 million yuan from August 7, 2018 to the disclosure date of this announcement, according to the evening announcement on December 26 The subsidy includes 300000 subsidy for coal-fired boiler demolition, and the rest is basically related to income and daily activities According to the company's announcement, the third quarter report of 2018 shows that the operating revenue of the first three quarters was 850 million yuan, an increase of 6.67% year-on-year; the net profit attributable to shareholders of the listed company was 5.65 million yuan, an increase of 102.31% year-on-year Kangchen pharmaceutical announced in the evening of December 24 that from December 25, 2017 to December 24, 2018, the company and its subsidiaries received nearly 47.97 million yuan of government subsidies related to income, accounting for 10.02% of the company's audited net profit in the past fiscal year According to the public third quarter report of 2018, the company's operating revenue in the first three quarters was 696 million yuan, a year-on-year increase of 78.57%; the net profit attributable to shareholders of the listed company was 157 million yuan, a year-on-year decrease of 62.69% Zixin pharmaceutical announced on October 25 that its subsidiary, Jilin Zixin shengongtang biotechnology, recently received a capital subsidy of 10.14 million yuan As of the announcement date, the subsidy funds have been received According to the announcement of Zixin pharmaceutical, the company's operating revenue in the first three quarters was 1.278 billion yuan, an increase of 70.25% year-on-year, and its net profit was 329 million yuan, an increase of 107.23% year-on-year Shuangcheng Pharmaceutical Co., Ltd recently, the subsidies for professional and technical talents and international certification awards for pharmaceutical manufacturers declared by Shuangcheng Pharmaceutical Co., Ltd were approved, and the subsidies have been transferred to the company's capital account recently Among them, the subsidy for professional and technical talents is 46500 yuan, and the international certification Award for pharmaceutical manufacturers is 1 million yuan, totaling 1046500 yuan The subsidy is related to the company's daily activities In addition, on November 13, Ningbo Shuangcheng, the holding subsidiary of Shuangcheng pharmaceutical, received a subsidy of about 1119500 yuan The subsidy is in cash and has been transferred to Shuangcheng pharmaceutical capital account on November 9, 2018 It is reported that the subsidiary company is a new area enterprise, and Ningbo will subsidize 60% of the land use tax paid by the new area enterprise in 2017 According to the public data, the company's operating revenue in the first three quarters was 259 million yuan, an increase of 61.39% year-on-year, with a net profit loss of nearly 32.45 million yuan.